Relative Bioavailability of BI 201335 (Capsule) Compared to Three Different Oral Solutions of BI 201335 Following Oral Administration in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Four-way Crossover Study)
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2015
Price : $35 *
At a glance
- Drugs Faldaprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 Jan 2013 New trial record